---
title: "Shandong Wohua Pharmaceutical Co., Ltd. (002107.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002107.SZ.md"
symbol: "002107.SZ"
name: "Shandong Wohua Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-21T05:35:08.760Z"
locales:
  - [en](https://longbridge.com/en/quote/002107.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002107.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002107.SZ.md)
---

# Shandong Wohua Pharmaceutical Co., Ltd. (002107.SZ)

## Company Overview

Shandong Wohua Pharmaceutical Co., Ltd. manufactures and sells pharmaceutical products in China. The company produces and sells tablets, granules, capsules, oral liquid, and pills; medicinal herb cultivation; and provides pharmaceutical technology consulting services. It also offers products including drugs for cardiovascular, cerebrovascular, and nervous system diseases, such as Wohua Xinkeshu tablets, Hedan tablets and capsules, Naoxueshu and Shenzhiling oral liquid, and Tongluo Huatan capsules; and drugs for musculoskeletal disorders, including Gusukang capsules/granules and Yidu Hanbi liquid; Yidu cold-rheumatism medicinal wine ingredients; brain blood circulation oral solution; Amber stone granules for urinary system diseases; Children's antipyretic granules for pediatric medication; Anti-itching granules for skin diseases; and Bile grass capsule for digestive and gynecological diseases, as well as Silkworm Nourishing Blood and Benefiting Kidney Granules for gynecological medication.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.wohua.cn](https://www.wohua.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-21T04:30:13.000Z

**Overall: B (0.30)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 58 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 6.77% |  |
| Net Profit YoY | 120.79% |  |
| P/B Ratio | 5.92 |  |
| Dividend Ratio | 3.84% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 3992372809.30 |  |
| Revenue | 816588136.66 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 15.68% | A |
| Profit Margin | 13.38% | B |
| Gross Margin | 77.96% | A |
| Revenue YoY | 6.77% | C |
| Net Profit YoY | 120.79% | A |
| Total Assets YoY | -7.56% | E |
| Net Assets YoY | -9.39% | D |
| Cash Flow Margin | 135.16% | B |
| OCF YoY | 6.77% | C |
| Turnover | 0.83 | B |
| Gearing Ratio | 28.76% | B |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Shandong Wohua Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "6.77%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "120.79%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "5.92",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "3.84%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "3992372809.30",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "816588136.66",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "15.68%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "13.38%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "77.96%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "6.77%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "120.79%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "-7.56%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-9.39%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "135.16%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "6.77%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.83",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "28.76%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 36.53 | 84/215 | 58.38 | 47.30 | 41.91 |
| PB | 5.92 | 196/215 | 5.81 | 5.31 | 4.93 |
| PS (TTM) | 4.89 | 124/215 | 5.15 | 4.80 | 4.44 |
| Dividend Yield | 3.84% | 20/215 | 3.64% | 1.92% | 1.68% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002107.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002107.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002107.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002107.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**